Compound ID | 3556
Class: Small molecule antibacterial agent
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Antimycobacterial |
| Mechanism of action: | Cytochrome bcc complex inhibitor (cytochrome b subunit of complex III inhibitor); QcrB inhibitor |
| Target Pathogen: | Active against Mycobacterium tuberculosis including multidrug-resistant strains |
| Description: | Synthetic compound; high selectivity index against THP-1, VERO, and HepG2 cell lines; high oral bioavailability in rats; shows synergistic effects with rifampicin and pyrazinamide |
| Year first mentioned: | 2015 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/122188597 |
| Guide to Pharmacology: | TB47 |
| Citation: | https://journals.asm.org/doi/10.1128/aac.00706-21?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed |